接受含奈韦拉平的高效抗逆转录病毒治疗（无论是否联用利福平）的HIV感染患者的血浆奈韦拉平水平及24周疗效
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
作者信息
Manosuthi Weerawat, Sungkanuparph Somnuek, Thakkinstian Ammarin, Rattanasiri Sasivimol, Chaovavanich Achara, Prasithsirikul Wisit, Likanonsakul Sirirat, Ruxrungtham Kiat
机构信息
Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand.
出版信息
Clin Infect Dis. 2006 Jul 15;43(2):253-5. doi: 10.1086/505210. Epub 2006 Jun 12.
Seventy human immunodeficiency virus (HIV)-infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P=.048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P>.05).
70名接受利福平治疗的人类免疫缺陷病毒（HIV）感染患者和70名未接受利福平治疗的HIV感染患者入选，每天接受400毫克基于奈韦拉平的高效抗逆转录病毒疗法。接受利福平治疗的患者在第8周和第12周时的血浆奈韦拉平平均水平较低（P = 0.048）。然而，两组在24周时的病毒学和免疫学结果并无差异（P>0.05）。
Zotero 插件